uniQure to Participate in Multiple Upcoming Industry Conferences in December
December 02 2019 - 7:00AM
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company
advancing transformative therapies for patients with severe medical
needs, today announced that it will participate in the following
upcoming conferences in December:
- Piper Jaffray Healthcare Conference, December 3 – 5,
New York City° Matt Kapusta, chief
executive officer, will participate in a fireside chat on Tuesday,
December 3, at 8:30 a.m.
ET.° Members of uniQure’s
management team will also participate in one-on-one investor
meetings throughout the day on Tuesday, December 3.
- Evercore ISI 2nd Annual HealthCONx Conference, December
3 – 5, Boston, MA° Matt Kapusta will
participate in a fireside at 9:30 a.m. ET on Wednesday, December
4° Members of uniQure’s management team will also participate
in one-on-one investor meetings throughout the day on Wednesday,
December 4.
- CBI’s Rare Disease Clinical Development & Access
Summit 2019, December 3 – 4, Arlington,
VA° Nick Li, senior director of
HEOR, will be joining a panel discussion on “Optimize Reimbursement
and Access Through Proactive Planning in Clinical Development” on
Wednesday, December 4 at 2 p.m. ET.
- American Society of Hematology (ASH) Annual Meeting,
December 7 – 10, Orlando,
Florida° uniQure management will
host an investor & analyst breakfast featuring Steven Pipe,
M.D., professor of pediatrics and pathology and pediatric medical
director of the hemophilia and coagulation disorders program at the
University of Michigan, who will review the one-year follow-up data
on etranacogene dezaparvovec presented at ASH.° The investor
& analyst breakfast will take place on Monday, December 9, from
7:00 a.m. to 8:00 a.m. ET, at the Hilton Orlando, Florida. The
meeting will be webcast live along with slides and can be accessed
by visiting the investor relations section of the Company’s website
at www.uniQure.com.
- Gene Therapy for Neurological Disorders, December 10 –
12, Boston, MA° Sander van Deventer,
EVP of research & product development, will present “Novel
AAV-delivered Gene Silencing Technologies Targeting the CNS:
Imaging of miRNAs & Therapeutic Efficacy in Huntington’s
Disease & SCA3” on Thursday, December 12 at 9:45 a.m. ET.
- Lega Italiana Ricerca Huntington, December 14, Rome,
Italy° Pavlina Konstantinova, VP of
new therapeutic target development, will be presenting “Development
of a microRNA-based Gene Therapy for Huntington’s Disease” on
Saturday, December 14 at 2:30 p.m. CET.
About uniQureuniQure is
delivering on the promise of gene therapy – single treatments with
potentially curative results. We are leveraging our modular and
validated technology platform to rapidly advance a pipeline of
proprietary gene therapies to treat patients with hemophilia B,
hemophilia A, Huntington's disease, Fabry disease, spinocerebellar
ataxia Type 3 and other diseases. www.uniQure.com
uniQure Contacts:
FOR INVESTORS:
Maria
E. Cantor |
Eva M.
Mulder |
Tom
Malone |
Direct: 339-970-7536 |
Direct: +31 20 240 6103 |
Direct: 339-970-7558 |
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Aug 2024 to Sep 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Sep 2023 to Sep 2024